Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
51.55% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
IRWD · Jun 30, 2026
IRONWOOD PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-26-091987General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
32.62% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
70.16% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
19.83% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
2.86% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History6 statesHistory building
Period transition
What moved in the state?
- Previous
- 4.81%
- Current
- 51.55%
- Delta
- 46.74%
- Previous
- 158.87%
- Current
- 32.62%
- Delta
- -126.25%
- Previous
- 68.14%
- Current
- 70.16%
- Delta
- 2.02%
- Previous
- 20.60%
- Current
- 19.83%
- Delta
- -0.77%
- Previous
- 3.43%
- Current
- 2.86%
- Delta
- -0.57%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Has State · IRONWOOD PHARMACEUTICALS INC →Transitioned To · IRWD Fundamental State →Transitioned To · IRWD CASH_GENERATION_INCREASED →Transitioned To · IRWD GROWTH_DECREASED →Transitioned To · IRWD PROFITABILITY_INCREASED →Transitioned To · IRWD R_AND_D_INTENSITY_DECREASED →Transitioned To · IRWD SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.